Table 2 Effect differences (95% confidence interval) between treatments on exacerbation rate [13, 15, 19, 33,34,35,36,37,38,39,40,41,42]
From: Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis
Treatment | Placebo | Benralizumab | Lebrikizumab | Dupilumab | Mepolizumab | Tralokinumab | Reslizumab | Tezepelumab |
|---|---|---|---|---|---|---|---|---|
Placebo |  | 0.485 (− 0.132, 1.080) | 0.903 (− 0.278, 2.380 | 0.903 (− 0.571, 2.570) | 0.485 (− 0.797, 1.750) | 0.755 (− 0.933, 2.640) | 0.589 (− 1.100, 2.280) | 1.170 (− 0.678, 3.150) |
Benralizumab | −0.485 (− 1.080, 0.132) |  | 0.445 (− 0.850, 1.870) | 0.439 (− 1.120, 2.070) | −0.019 (− 1.300, 1.380) | 0.283 (− 1.490, 2.130) | 0.100 (− 1.620, 1.870) | 0.697 (− 1.170, 2.670) |
Lebrikizumab | −0.903 (− 2.380, 0.278) | −0.445 (− 1.870, 0.850) |  | 0.006 (− 1.950, 1.760) | − 0.483 (− 2.110, 1.280) | −0.172 (− 2.180, 1.920) | −0.361 (− 2.390, 1.720) | 0.258 (− 1.950, 2.460) |
Dupilumab | −0.903 (− 2.570, 0.571) | −0.439 (− 2.070, 1.120) | −0.006 (− 1.760, 1.950) |  | − 0.472 (− 2.330, 1.530) | −0.164 (− 2.390, 2.160) | −0.347 (− 2.430, 1.740) | 0.258 (− 2.070, 2.760) |
Mepolizumab | −0.485 (− 1.750, 0.797) | 0.019 (− 1.380, 1.300) | 0.483 (− 1.280, 2.110) | 0.472 (− 1.530, 2.330) |  | 0.317 (− 1.750, 2.320) | 0.122 (− 1.980, 2.150) | 0.709 (− 1.580, 2.980) |
Tralokinumab | −0.755 (− 2.640, 0.933) | − 0.283 (− 2.130, 1.490) | 0.172 (− 1.920, 2.180) | 0.164 (− 2.160, 2.390) | −0.317 (− 2.320, 1.750) |  | − 0.188 (− 2.620, 2.230) | 0.408 (− 2.000, 2.970) |
Reslizumab | − 0.589 (− 2.280, 1.100) | −0.100 (− 1.870, 1.620) | 0.361 (− 1.720, 2.390) | 0.347 (− 1.740, 2.430) | −0.122 (− 2.150, 1.980) | 0.188 (− 2.230, 2.620) |  | 0.604 (− 1.810, 3.090) |
Tezepelumab | −1.170 (− 3.150, 0.678) | − 0.697 (− 2.670,1.170) | −0.258 (− 2.460, 1.950) | −0.258 (− 2.760,2.070) | −0.709 (− 2.980, 1.580) | −0.408 (− 2.970, 2.000) | −0.604 (− 3.090, 1.810) |  |